Immix Biopharma
IMMX
31 hedge funds and large institutions have $8.77M invested in Immix Biopharma in 2024 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 11 reducing their positions, and 6 closing their positions.
3.16% less ownership
Funds ownership: 19.93% → 16.77% (-3.2%)
11% less funds holding
Funds holding: 35 → 31 (-4)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
44% less capital invested
Capital invested by funds: $15.7M → $8.77M (-$6.94M)
45% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 11
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$327K |
| 2 |
CCC
Cable Car Capital
San Francisco,
California
|
+$289K |
| 3 |
I
INVST
Indianapolis,
Indiana
|
+$62K |
| 4 |
Squarepoint
New York
|
+$52.9K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$39.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$341K |
| 2 |
Renaissance Technologies
New York
|
-$255K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$236K |
| 4 |
CCM
Corsair Capital Management
New York
|
-$127K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$79.3K |
IMMX Hedge Fund Activity: Q2 2024 in Review
31 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Immix Biopharma (IMMX) for Q2 2024, worth a combined $8.77M — down 44% from $15.7M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of IMMX and 5 opened new positions — a net loss of 1 holder — while 11 trimmed existing stakes and 6 added.
The largest buyer was Vanguard Group, adding an estimated $327K. The largest seller was AIGH Capital Management, cutting an estimated $341K.
- 31 institutional investors held Immix Biopharma (IMMX) as of Q2 2024, down from 35 in Q1 2024.
- Funds reported $8.77M of Immix Biopharma stock for Q2 2024, down 44% quarter-over-quarter.
- 5 funds opened new Immix Biopharma positions in Q2 2024 and 6 closed out, a net change of -1 holder.
- The largest Immix Biopharma buyer in Q2 2024 was Vanguard Group, an estimated $327K added.
- The largest Immix Biopharma seller in Q2 2024 was AIGH Capital Management, an estimated $341K sold.
Based on aggregated 13F filings for Q2 2024.